PT  - JOURNAL ARTICLE
AU  - Dhib, Donia
AU  - Mejri, Nesrine
AU  - Berrazaga, Yosra
AU  - Rachdi, Haifa
AU  - Saadi, Myriam
AU  - Daoud, Nouha
AU  - Hammouda, Boussen
TI  - EP035/#866  Adjuvant treatment for luminal breast cancer of intermediate prognosis
AID  - 10.1136/ijgc-2023-IGCS.159
DP  - 2023 Nov 01
TA  - International Journal of Gynecologic Cancer
PG  - A96--A97
VI  - 33
IP  - Suppl 4
4099  - http://ijgc.bmj.com/content/33/Suppl_4/A96.3.short
4100  - http://ijgc.bmj.com/content/33/Suppl_4/A96.3.full
SO  - Int J Gynecol Cancer2023 Nov 01; 33
AB  - Introduction Our retrospective study analyzed the adjuvant treatment decision for localized intermediate risk breast cancer as well as the parameters leading to protocol de-escalation and It’s impact on outcome.Methods A retrospective study gathering 127 patients with localized (pT1–3pN1 or pT2–3pN0) luminal breast cancers; We analyzed the protocol decision and the parameters leading to de-escalation as well as the therapeutic results.Results Median age was 52 years and 47% were pre-menopausal. One third of the tumors were pN0, mean tumor size (pT) was 28 mm, and grade III in 27.4% of cases. Most of the tumors (66%) were of Luminal B and the mean ki67 was 26%.Adjuvant protocol was chemotherapy for 119 patients, sequential in 80.3% of cases and Docetaxel-Cyclophosphamide(TC) in 13.4% of cases.Twenty-four cases were reviewed by the medical comittee, and a therapeutic de-escalation was decided for 12 patients among them, based on TC(6 patients) and hormone therapy for 6 patients.The patients characteristics are resumed in table 1.Concerning toxicity, we observed a higher rate of neutropenia (47.5% vs 11.8% p=0.04) and febrile neutropenia G3–4 (20.6% vs. 0% p=0.02)with sequential chemotherapy. With a median follow-up of 51 months, overall survival was 94% at 5 years.The choice of adjuvant treatment didn’t significantly influence overall survival.View this table:Abstract EP035/#866 Table 1 Clinico-pathological characteristic of the patientsConclusion/Implications De-escalation of adjuvant therapy in patients with intermediate risk localized breast cancer didn’t impair overall survival.